FLGT (Fulgent Genetics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by FLGT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-03 | Hanlin Gao | Chief Scientific Officer | Sell | — | — |
| 2026-09-03 | Jian Xie | President and COO | Sell | — | — |
| 2026-09-03 | Paul Kim | CFO and Treasurer | F | — | — |
| 2026-09-03 | Ming Hsieh | Chief Executive Officer | F | — | — |
| 2026-08-28 | Hanlin Gao | Chief Scientific Officer | Sell | — | — |
| 2026-08-28 | Jian Xie | President and COO | Sell | — | — |
| 2026-08-28 | Paul Kim | CFO and Treasurer | F | — | — |
| 2026-08-28 | Ming Hsieh | Chief Executive Officer | F | — | — |
| 2026-07-28 | Hanlin Gao | Chief Scientific Officer | F | — | — |
| 2026-07-28 | Jian Xie | President and COO | F | — | — |
| 2026-07-28 | Paul Kim | CFO and Treasurer | F | — | — |
| 2026-06-03 | Hanlin Gao | Chief Scientific Officer | Sell | — | — |
| 2026-06-03 | Paul Kim | CFO and Treasurer | F | — | — |
| 2026-06-03 | Jian Xie | President and COO | Sell | — | — |
| 2026-06-03 | Ming Hsieh | Chief Executive Officer | F | — | — |
| 2026-05-28 | Paul Kim | CFO and Treasurer | F | — | — |
| 2026-05-28 | Jian Xie | President and COO | Sell | — | — |
| 2026-05-28 | Hanlin Gao | Chief Scientific Officer | Sell | — | — |
| 2026-05-27 | Ming Hsieh | Chief Executive Officer | F | — | — |
| 2026-05-18 | REGINA E GROVES | Director | A | — | — |
| 2026-05-18 | Linda Dong | Director | A | — | — |
| 2026-05-18 | Michael Nohaile | Director | A | — | — |
| 2026-04-28 | Paul Kim | CFO and Treasurer | F | — | — |
| 2026-04-28 | Jian Xie | President and COO | F | — | — |
| 2026-04-28 | Hanlin Gao | Chief Scientific Officer | F | — | — |
| 2026-03-11 | Ming Hsieh | Chief Executive Officer | J | — | — |
| 2026-03-02 | Hanlin Gao | Chief Scientific Officer | F | — | — |
| 2026-03-02 | Jian Xie | President and COO | F | — | — |
| 2026-03-02 | Paul Kim | CFO and Treasurer | F | — | — |
| 2026-03-02 | Ming Hsieh | Chief Executive Officer | F | — | — |
| 2026-02-25 | Hanlin Gao | Chief Scientific Officer | MIXED | — | — |
| 2026-02-25 | Ming Hsieh | Chief Executive Officer | MIXED | — | — |
| 2026-02-25 | Jian Xie | President and COO | MIXED | — | — |
| 2026-02-25 | Paul Kim | CFO and Treasurer | MIXED | — | — |
| 2026-01-28 | Hanlin Gao | Chief Scientific Officer | F | — | — |
| 2026-01-28 | Paul Kim | CFO and Treasurer | F | — | — |
| 2026-01-28 | Jian Xie | President and COO | F | — | — |
| 2025-12-03 | Paul Kim | CFO and Treasurer | F | — | — |
| 2025-12-03 | Hanlin Gao | Chief Scientific Officer | Sell | — | — |
| 2025-12-03 | Jian Xie | President and COO | Sell | — | — |
| 2025-12-01 | Hanlin Gao | Chief Scientific Officer | Sell | — | — |
| 2025-12-01 | Paul Kim | CFO and Treasurer | F | — | — |
| 2025-12-01 | Jian Xie | President and COO | Sell | — | — |
| 2025-12-01 | Ming Hsieh | Chief Executive Officer | F | — | — |
| 2025-11-25 | Hanlin Gao | Chief Scientific Officer | Sell | — | — |
| 2025-11-25 | Paul Kim | CFO and Treasurer | F | — | — |
| 2025-11-25 | Ming Hsieh | Chief Executive Officer | F | — | — |
| 2025-11-25 | Jian Xie | President and COO | Sell | — | — |
| 2025-11-21 | Jian Xie | President and COO | MIXED | — | — |
| 2025-10-28 | Hanlin Gao | Chief Scientific Officer | F | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 8,609,488 | — |
| — | 10%+ Owner | 2,025,623 | — |
| — | Chief Scientific Officer | 986,117 | — |
| — | Chief Executive Officer | 886,952 | — |
| — | President and COO | 580,740 | — |
| — | CFO and Treasurer | 356,543 | — |
| — | Director | 38,758 | — |
| — | Director | 28,099 | — |
| — | Director | 24,578 | — |
| — | Director | 10,000 | — |
| — | Director | 8,000 | — |
| — | Director | 6,842 | — |
| — | Director | 5,100 | — |
| — | Director | 2,000 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the FLGT quote page; the site-wide leaderboard is on the insider transactions hub.